Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
LAT-010 by Latticon Antibody Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
LAT-010 is under clinical development by Latticon Antibody Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According...
LAT-010 by Latticon Antibody Therapeutics for Renal Cell Carcinoma: Likelihood of Approval
LAT-010 is under clinical development by Latticon Antibody Therapeutics and currently in Phase II for Renal Cell Carcinoma. According to...
LAT-010 by Latticon Antibody Therapeutics for Hepatocellular Carcinoma: Likelihood of Approval
LAT-010 is under clinical development by Latticon Antibody Therapeutics and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData,...
LAT-010 by Latticon Antibody Therapeutics for Gastric Cancer: Likelihood of Approval
LAT-010 is under clinical development by Latticon Antibody Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData,...
LAT-010 by Latticon Antibody Therapeutics for Melanoma: Likelihood of Approval
LAT-010 is under clinical development by Latticon Antibody Therapeutics and currently in Phase II for Melanoma. According to GlobalData, Phase...
LAT-010 by Latticon Antibody Therapeutics for Colorectal Cancer: Likelihood of Approval
LAT-010 is under clinical development by Latticon Antibody Therapeutics and currently in Phase II for Colorectal Cancer. According to GlobalData,...
LAT-010 by Latticon Antibody Therapeutics for Ovarian Cancer: Likelihood of Approval
LAT-010 is under clinical development by Latticon Antibody Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData,...
LAT-010 by Latticon Antibody Therapeutics for Breast Cancer: Likelihood of Approval
LAT-010 is under clinical development by Latticon Antibody Therapeutics and currently in Phase II for Breast Cancer. According to GlobalData,...